Training, guideline access and knowledge of antiretroviral interactions: Is the South African private sector being left behind?

Authors

  • BS Chisholm National HIV and TB Healthcare Worker Hotline, Medicines Information Centre, Division of Clinical Pharmacology, Faculty of Health Sciences, Department of Medicine, University of Cape Town, South Africa
  • AM Swart National HIV and TB Healthcare Worker Hotline, Medicines Information Centre, Division of Clinical Pharmacology, Faculty of Health Sciences, Department of Medicine, University of Cape Town, South Africa
  • M Blockman Division of Clinical Pharmacology, Faculty of Health Sciences, Department of Medicine, University of Cape Town, South Africa

DOI:

https://doi.org/10.7196/SAMJ.2022.v112i10.16427

Keywords:

Antiretrovirals, TB, HIV

Abstract

Background. South Africa (SA) has the largest antiretroviral therapy programme in the world. While the majority of the country accesses healthcare in the public sector, 15.2% access private healthcare. In 2019, dolutegravir was introduced as first-line treatment for HIV. Dolutegravir has clinically significant interactions with numerous commonly used medicines, e.g. rifampicin and cation-containing medicines such as calcium and iron. They require dosage adjustments, detailed in public and private HIV guidelines.
Objectives. To describe SA healthcare workers’ guideline access, training and knowledge of dolutegravir’s interactions, focusing on
differences between the public and private sectors.
Methods. A cross-sectional, descriptive study was done using an online survey of healthcare workers in the field of HIV in SA, conducted by the National HIV and TB Healthcare Worker Hotline. Convenience sampling was used, with electronic dissemination to users of the hotline and by relevant HIV-focused organisations. Simple descriptive statistics and statistical analyses were used.
Results. A total of 1 939 surveys were analysed, with 22% from the private sector. Training on the dolutegravir guidelines was received
by significantly fewer healthcare workers in the private sector v. the public sector: 42.4% (95% confidence interval (CI) 37 - 48) v. 67.5%
(95% CI I 65 - 70), respectively. Significantly fewer healthcare workers in the private sector had access to the guidelines (63.8%; 95% CI
59 - 69 v. 78.8%; 95% CI 77 - 81). When asked if they were aware that dolutegravir has interactions, just over half (56.9%) of healthcare
workers in the private sector responded ‘yes’, 24.6% responded ‘no’ and 18.5% did not answer. Of those who were aware that dolutegravir has interactions, 48.9% knew that dolutegravir interacts with calcium, 44.6% with iron and 82.0% with rifampicin. Private sector knowledge of dosing changes was lower for all interacting drugs, with the difference only significant for calcium and iron. Private sector healthcare workers reported significantly lower levels of counselling on dolutegravir use in all appropriate situations.
Conclusion. Private sector healthcare worker access to HIV training and guidelines requires attention. In a high-burden HIV setting such as SA, it is vital that healthcare workers across all professions, in both the public and private sector, know how to adjust antiretroviral dosing due to clinically significant interactions. Without these adjustments, there is a risk of treatment failure, increased mother-to-child transmission and morbidity and mortality

References

Statistics South Africa. Mid-year population estimates: 2021. Pretoria: StatsSA, 2021. http://www.statssa.gov. za/publications/P0302/P03022021.pdf (accessed 30 December 2021).

Joint United Nations Programme on HIV/AIDS. UNAIDS Data 2021. Geneva: UNAIDS, 2021. https://www. unaids.org/sites/default/files/media_asset/JC3032_AIDS_Data_book_2021_En.pdf (accessed 4 January 2022).

Statistics South Africa. General household survey: 2020. Pretoria: StatsSA, 2021. http://www.statssa.gov. za/publications/P0318/P03182020.pdf (accessed 30 December 2021).

Council for Medical Schemes. Council for Medical Schemes Annual Report 2020/21. Annexure E: Utilisation of healthcare services. Pretoria: CMS, 2021. https://www.medicalschemes.co.za/cms-annual- report-2020-21/ (accessed 18 January 2022).

Govender K, Girdwood S, Letswalo D, Long L, Meyer-Rath G, Miot J. Primary healthcare seeking behaviour of low-income patients across the public and private health sectors in South Africa. BMC Public Health 2021;21:1649. https://doi.org/10.1186/s12889-021-11678-9

World Health Organization. WHO recommends dolutegravir as preferred HIV treatment option in all populations. Mexico City: WHO, 2019. https://www.who.int/news/item/22-07-2019-who-recommends- dolutegravir-as-preferred-hiv-treatment-option-in-all-populations (accessed 13 September 2021).

National Department of Health, South Africa. National Consolidated Guidelines for the Management of HIV in Adults, Adolescents, Children and Infants and Prevention of Mother-to-Child Transmission. Pretoria: NDoH, 2020. https://www.knowledgehub.org.za/system/files/elibdownloads/2020-07/ National%20Consolidated%20Guidelines%2030062020%20signed%20PRINT%20v7.pdf (accessed 11 October 2021).

Nel J, Dlamini S, Meintjies G, et al. Southern African HIV clinicians society guidelines for antiretroviral therapy in adults: 2020 update. South Afr J HIV Med 2020;21(1):a1115. https://doi.org/10.4102/ sajhivmed.v21i1.1115

Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400 mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. E Clin Med 2020;28:100573. https://doi.org/10.1016/j.eclinm.2020.100573

Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. AIDS Rev 2015;17(1):56-64.

Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co- administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 2011;66(7):1567-1572. https://doi.org/10.1093/jac/dkr139

Song I, Borland J, Arya N, Wynne B, Piscitelli S. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol 2015;55(5):490-496. https://doi. org/10.1002/jcph.439

SongI,ZongJ,BorlandJ,etal.Theeffectofdolutegravironthepharmacokineticsofmetformininhealthy subjects. J Acquir Immun Defic Syndr 2016;72(4):400-407. https://doi.org/10.1097/qai.0000000000000983

Wang X, Cerrone M, Ferretti F, et al. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. Int J Antimicrob Agents 2019;54(2):202-206. https://doi.org/10.1016/j.ijantimicag.2019.04.009

Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: A multicenter, noncomparative, open-label, randomised trial. Clin Infect Dis 202;70(4):549-556. https://doi.org/10.1093/cid/ciz256

Song I, Weller S, Patel J, et al. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. Eur J Clin Pharmacol 2016;72(6):665-670. https://doi.org/10.1007/s00228-016-2020-6 17. Tivicay (summary of product characteristics). Amersfoort: ViiV Healthcare, 2018. https://www.ema. europa.eu/en/documents/product-information/tivicay-epar-product-information_en.pdf (accessed

December 2021).

Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions

among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010;50(10):1419-1421.

https://doi.org/10.1086/652149

Arshad S, Rothberg M, Rastegar DA, Spooner LM, Skiest D. Survey of physician knowledge regarding antiretroviral medications in hospitalised HIV-infected patients. J Int AIDS Soc 2009;12:1. https://doi. org/10.1186/1758-2652-12-1

Kuemmerle A, Sikalengo G, Vanobberghen F, et al. Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: A prospective questionnaire-based study. J Antimicrob Chemother 2021;76(10):2681- 2689. https://doi.org/10.1093/jac/dkab254

Chisholm B, Swart A, Blockman M. South African healthcare workers’ knowledge of dolutegravir’s drug-drug interactions in the first year of its rollout: A cross-sectional online survey. J Int AIDS Soc 2022;25(3):e25885. https://doi.org/10.1002/jia2.25885

Statistics South Africa. Mid-year population estimates: 2020. Pretoria: StatsSA, 2021. http://www.statssa. gov.za/publications/P0302/P03022020.pdf (accessed 7 June 2021).

Solomons DI, van der Merwe AS, Esterhuizen TM, Crowley T. Factors influencing the confidence and knowledge of nurses prescribing antiretroviral treatment in a rural and urban district in the Western Cape province. South Afr J HIV Med 2019;20(1):923. https://doi.org/10.4102/sajhivmed.v20i1.923

Boffa J, Moyo S, Chikovore J, et al. Quality of care for tuberculosis and HIV in the private health sector: A cross-sectional, standardised patient study in South Africa. BMJ Glob Health 2021;6:e005250. https:// doi.org/10.1136/bmjgh-2021-005250

Downloads

Published

2022-10-05

Issue

Section

Research

How to Cite

1.
Chisholm B, Swart A, Blockman M. Training, guideline access and knowledge of antiretroviral interactions: Is the South African private sector being left behind? . S Afr Med J [Internet]. 2022 Oct. 5 [cited 2024 Jul. 14];112(10):806-11. Available from: https://samajournals.co.za/index.php/samj/article/view/263

Similar Articles

1-10 of 70

You may also start an advanced similarity search for this article.